# Amarin Corporation plc (AMRN)

Source: https://www.quantisnow.com/company/AMRN
Generated: 2026-11-13T14:44:47.974Z

- Ticker: AMRN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0000897448
- Website: amarincorp.com

## About

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

## Latest AMRN news and filings

- 2026-11-09 13:00 UTC [Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026](https://www.quantisnow.com/insight/amarin-highlights-new-data-on-lipoproteina-and-other-apolipoprotein-b-6780326)
- 2026-10-28 11:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Amarin Corporation plc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-amarin-corporation-plc-6760460)
- 2026-10-28 11:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Amarin Corporation plc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-amarin-corporation-plc-6760459)
- 2026-10-28 11:00 UTC [Earnings Date] [Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income](https://www.quantisnow.com/insight/amarin-reports-2026-third-quarter-financial-results-achieves-positive-net-6760387)
- 2026-10-25 12:11 UTC [Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)](https://www.quantisnow.com/insight/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-6756744)
- 2026-10-21 12:00 UTC [Earnings Date] [Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026](https://www.quantisnow.com/insight/amarin-to-report-third-quarter-2026-financial-results-and-host-6752942)
- 2026-08-31 12:15 UTC [Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026](https://www.quantisnow.com/insight/amarin-highlights-new-reduce-it-and-mechanistic-data-presented-at-european-6699194)
- 2026-08-28 12:15 UTC [New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients](https://www.quantisnow.com/insight/new-reduce-it-legacy-analysis-presented-at-european-society-of-cardiology-6697953)
- 2026-08-24 12:15 UTC [New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026](https://www.quantisnow.com/insight/new-analyses-from-reduce-it-and-epa-mechanistic-data-to-be-6692167)
- 2026-08-21 12:22 UTC [Analyst Coverage Resumed] [Analyst resumed coverage on Amarin with a new price target](https://www.quantisnow.com/insight/analyst-resumed-coverage-on-amarin-with-a-new-price-target-6690811)
- 2026-08-03 20:30 UTC [SEC Form 4] [SVP, CFO Fishman Peter L. converted options into 313 units of American Depositary Share and covered exercise/tax liability with 155 units of American Depositary Share, increasing direct ownership by 2% to 7,619 units (SEC Form 4)](https://www.quantisnow.com/insight/svp-cfo-fishman-peter-l-converted-options-into-313-units-6660107)
- 2026-07-29 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Amarin Corporation plc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-amarin-corporation-plc-6654054)
- 2026-07-29 20:30 UTC [SEC Form 8-K] [Amarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/amarin-corporation-plc-filed-sec-form-8-k-results-of-operations-6654040)
- 2026-07-29 11:00 UTC [Earnings Date] [Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence](https://www.quantisnow.com/insight/amarin-reports-2026-second-quarter-financial-results-demonstrating-early-success-6652572)
- 2026-07-15 21:00 UTC [SEC Form 4] [EVP, Chief Scientific Officer Ketchum Steven B converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,887 units of American Depositary Shares, increasing direct ownership by 4% to 42,680 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-scientific-officer-ketchum-steven-b-converted-options-into-6638559)
- 2026-07-15 21:00 UTC [SEC Form 4] [EVP, Chief Operating Officer Keenan David Paul converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,926 units of American Depositary Shares, increasing direct ownership by 15% to 13,470 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-operating-officer-keenan-david-paul-converted-options-into-6638556)
- 2026-07-15 21:00 UTC [SEC Form 4] [SVP, CFO Fishman Peter L. converted options into 2,447 units of American Depositary Shares and covered exercise/tax liability with 1,206 units of American Depositary Shares, increasing direct ownership by 20% to 7,461 units (SEC Form 4)](https://www.quantisnow.com/insight/svp-cfo-fishman-peter-l-converted-options-into-2447-units-6638553)
- 2026-07-15 21:00 UTC [SEC Form 4] [EVP, Chief Legal Officer Provoost Jonathan converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,264 units of American Depositary Shares, increasing direct ownership by 110% to 4,624 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-legal-officer-provoost-jonathan-converted-options-into-3688-6638549)
- 2026-07-15 12:00 UTC [Earnings Date] [Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026](https://www.quantisnow.com/insight/amarin-to-report-second-quarter-2026-financial-results-and-host-6637616)
- 2026-06-30 21:20 UTC [SEC Form 4] [President and CEO Berg Aaron converted options into 6,250 units of American Depositary Shares and covered exercise/tax liability with 3,197 units of American Depositary Shares, increasing direct ownership by 4% to 85,648 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-berg-aaron-converted-options-into-6250-units-6621295)
- 2026-06-30 20:15 UTC [Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape](https://www.quantisnow.com/insight/amarin-reaffirms-the-proven-guideline-recommended-role-of-vascepa-icosapent-ethyl-6620870)
- 2026-05-27 12:00 UTC [New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia](https://www.quantisnow.com/insight/new-reduce-it-analysis-presented-at-the-european-atherosclerosis-society-eas-6573866)
- 2026-05-15 01:30 UTC [SEC Form 8-K] [Amarin Corporation plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/amarin-corporation-plc-filed-sec-form-8-k-submission-of-matters-6555362)
- 2026-04-29 11:06 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Amarin Corporation plc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-amarin-corporation-plc-6520018)
- 2026-04-29 11:05 UTC [SEC Form 8-K] [Amarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/amarin-corporation-plc-filed-sec-form-8-k-results-of-operations-6520014)
- 2026-04-29 11:00 UTC [Earnings Date] [Amarin Reports 2026 First Quarter Financial Results](https://www.quantisnow.com/insight/amarin-reports-2026-first-quarter-financial-results-6519922)
- 2026-04-22 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Bonfiglio Patrice Eadon](https://www.quantisnow.com/insight/sec-form-4-filed-by-bonfiglio-patrice-eadon-6510854)
- 2026-04-21 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Cohen Paul](https://www.quantisnow.com/insight/sec-form-4-filed-by-cohen-paul-6508846)
- 2026-04-21 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Sullivan Diane E.](https://www.quantisnow.com/insight/sec-form-4-filed-by-sullivan-diane-e-6508840)
- 2026-04-21 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Sterling Louis Iii](https://www.quantisnow.com/insight/sec-form-4-filed-by-sterling-louis-iii-6508839)
- 2026-04-21 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Horn Keith](https://www.quantisnow.com/insight/sec-form-4-filed-by-horn-keith-6508838)
- 2026-04-21 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Odysseas Kostas D](https://www.quantisnow.com/insight/sec-form-4-filed-by-odysseas-kostas-d-6508837)
- 2026-04-21 21:00 UTC [SEC Form 4] [SEC Form 4 filed by O'Connor Oliver](https://www.quantisnow.com/insight/sec-form-4-filed-by-oconnor-oliver-6508835)
- 2026-04-15 12:00 UTC [Earnings Date] [Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026](https://www.quantisnow.com/insight/amarin-to-report-first-quarter-2026-financial-results-and-host-6500547)
- 2026-04-10 21:00 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Amarin Corporation plc](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-amarin-corporation-plc-6496586)
- 2026-04-08 12:00 UTC [American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction](https://www.quantisnow.com/insight/american-college-of-cardiology-acc-scientific-sessions-2026-underscore-the-6492217)
- 2026-04-02 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Fishman Peter L.](https://www.quantisnow.com/insight/sec-form-4-filed-by-fishman-peter-l-6485121)
- 2026-03-30 21:57 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Amarin Corporation plc](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-amarin-corporation-plc-6477107)
- 2026-03-27 21:00 UTC [SEC Form 8-K] [Amarin Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amarin-corporation-plc-filed-sec-form-8-k-leadership-update-financial-6475068)
- 2026-03-18 12:30 UTC [Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline](https://www.quantisnow.com/insight/amarin-highlights-guideline-recommended-role-of-icosapent-ethyl-in-managing-6455418)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AMRN
- Earnings history: https://www.quantisnow.com/earnings/AMRN
- Dividend history: https://www.quantisnow.com/dividends/AMRN
- Insider transactions: https://www.quantisnow.com/insiders/AMRN
- Options chain: https://www.quantisnow.com/options/AMRN
- SEC 8-K filings only: https://www.quantisnow.com/company/AMRN/8-k
- RSS and alerts for AMRN: https://www.quantisnow.com/docs/rss-feeds.md